We performed a 5-question survey of 22 oncologists in the US to gauge current prescribing practices for breast cancer treatments, with a focus on HR+/HER2- recurrent or metastatic breast cancer. Drugs discussed:

•Ibrance (palbociclib, PFE)

•Afinitor (everolimus, NVS)

•Halaven (eribulin, Eisai)

•Abraxane (nab-paclitaxel, CELG)

•Doxil (pegylated liposomal doxorubicin, JNJ)

•Gemzar (gemcitabine, LLY)

•Xeloda (capecitabine, Roche)